University of South Florida Researcher Yields New Findings on Migraine [Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)].

A recent study conducted by researchers at the University of South Florida analyzed data from the FDA Adverse Event Reporting System (FAERS) to investigate the relationship between triptans (sumatriptan, rizatriptan, and zolmitriptan) and cardiovascular adverse events in migraine treatment. The study found that women reported more cardiovascular adverse events with rizatriptan and zolmitriptan compared to men, and individuals aged 18-64 had the highest risk. Sumatriptan was associated with a higher cardiovascular risk than rizatriptan and zolmitriptan, with most deaths and serious cases documented for sumatriptan. This research may help in evaluating the risk of triptan treatment for migraines. [Extracted from the article]